Highlight Therapeutics, S.L.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Highlight Therapeutics, S.L.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Admedus and its product mix was an unfolding success story – and still is, due to a restructuring of activities and a resetting of aims that have ensured the Australia-US tissue engineering company does not miss out on the opportunities it has crafted for itself. Chairman and interim CEO Wayne Paterson explains what changes were required and why.
- Other Names / Subsidiaries
- Bioncotech Therapeutics S.L